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1. Introduction 
Replacement heifers are critical to dairy herd productivity because they represent the future 
milking and breeding stock of all dairy operations. The goal should be to provide an 
environment for heifers to develop full lactation potential at the desired age with minimal 
expense. Animal health and well-being play vital roles in achieving this potential, and one 
disease that can influence future productivity is heifer mastitis caused by Staphylococcus 
aureus, the coagulase-negative staphylococci (CNS), and the environmental streptococci 
(Streptococcus uberis, Streptococcus dysgalactiae). 
Unfortunately, most producers regard young dairy heifers as uninfected, and the presence 
of mastitis is not observed until freshening or until the first clinical flare-up in early 
lactation. Thus, animals may carry intramammary infections (IMI) for a year or more before 
they are diagnosed with mastitis (Boddie et al., 1987). The greatest development of milk-
producing tissue in the udder occurs during the first pregnancy, so it is important to protect 
the heifer mammary gland from pathogenic microorganisms to ensure maximum milk 
production during the first and future lactations. In the USA, Louisiana researchers found 
that if bred heifers infected with Staph. aureus were left untreated, they produced 10% less 
milk in early lactation than those receiving therapy (Owens et al., 1991; Trinidad et al., 
1990c). Likewise, research in New Zealand demonstrated that Staph. aureus mastitis in 
heifers resulted in significant production losses during the first lactation, which carried over 
into the subsequent lactation because of damage to milk-producing tissues of the udder 
(Woolford et al., 1983). 
2. Prevalence of mastitis in unbred and primigravid heifers 
A greater focus on heifer mastitis began in the mid 1980s after several dairy producers in 
Louisiana complained to university researchers that a large percentage of their heifers were 
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freshening with clinical mastitis. Subsequent study of breeding age animals in a research 
herd revealed that IMI may be diagnosed as early as 6 months of age, and infections 
persisted throughout pregnancy and into lactation (Boddie et al., 1987). Other studies 
demonstrated that greater than 90% of breeding age and bred heifers (12 - 24 months of age) 
may be infected (Trinidad et al., 1990b). Most of the infections were shown to be caused by 
the CNS (Staphylococcus chromogenes and Staphylococcus hyicus) followed by Staph. aureus 
(20%). Mixed isolates of CNS and Streptococcus species were also found. 
The prevalence of mastitis in 10 unbred Jersey heifers (10 - 12 months of age) in Louisiana 
was initially evaluated in 1985 and monitored over a 1-year period, which covered breeding 
age and gestation (Boddie et al., 1987). Samplings from the teat skin, teat canal, and 
mammary secretion were performed bimonthly and continued through time of calving. For 
bacteriologic analysis, a total of 388 samples from teat skin, 388 from teat canal keratin, and 
216 from secretions were examined; not all quarters contained sufficient volumes of 
secretions.  
For teat skin, staphylococci were isolated on mannitol salt agar, and the predominant colony 
type of a particular isolate based on color, rough/smooth, size, hemolytic pattern, and 
appearance was collected, sub-plated for culture on blood agar, and identified to the species 
level (Boddie et al., 1987). Staphylococcus xylosus (20.9%) and Staph. chromogenes (14.9%) were 
the predominant flora isolated from teat skin, followed by Staph. warneri (6.7%), Staph. sciuri 
(6.2%), Staph. aureus (2.8%), Staph. hyicus (1.3%), and Staph. simulans (1.3%). The most 
prevalent bacteria found in teat canals were Staph. chromogenes (41.0%), followed by Staph. 
hyicus (16.8%), Staph. aureus (10.0%), Staph. xylosus (1.0%), Staph. warneri (0.8%), and Staph. 
sciuri (0.5%).  
In mammary secretions, Staph. chromogenes (49.5%) was the predominant organism, 
followed by Staph. hyicus (21.3%), Staph. aureus (13.0%), Streptococcus uberis (1.4), and Staph. 
xylosus (0.9%). The CNS species in teat canals and in secretions from a particular mammary 
quarter were present at the first sampling, and the same CNS species were isolated from teat 
canals and secretions from the same individual quarters with each successive sampling of 
the trial. Also, there appeared to be a correlation between colonization of the teat canal and 
IMI. For example, the major CNS species colonizing the teat canal (Staph. chromogenes 
(41.0%), Staph. hyicus (16.8%), Staph. aureus (10.0%), and Staph. xylosus (1.0%)) were also the 
predominant organisms causing IMI (Staph. chromogenes (49.5%), Staph. hyicus (21.3%), Staph. 
aureus (13.0%), and Staph. xylosus (0.9%)). Thus, teat canals infected with Staph. chromogenes 
(41.0%) were positively correlated with secretions (49.5%) infected with these bacteria. The 
overall correlation between teat canal colonization and IMI was 82.2% across these 4 CNS 
species.  
This initial study (Boddie et al., 1987) indicated that teat skin, teat canals, and mammary 
secretions of heifers are colonized with CNS as well as Staph. aureus at an early age, and that 
infections may persist for up to 1 year. Species identification demonstrated that nearly all 
isolates from the same quarter throughout the study were the same biovariant based on the 
API Staph-Ident System as previously modified (Watts et al., 1984), which supports the 
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contention that isolates from each quarter over time were from persistent infections and not 
from new IMI occurring between sampling periods. Although the percentage of Staph. 
aureus isolates was lower than CNS, presence of this major pathogen demonstrated that it 
colonized teat canals at a much earlier age than documented previously (Rendel & 
Sundberg, 1962). 
In a subsequent herd survey (Trinidad et al., 1990b), the prevalence of mastitis in breeding 
age and pregnant heifers was determined in 4 commercial dairies. Teat canal keratin and 
secretion samples were collected from 116 Jersey heifers, and results revealed that teat canal 
colonizations were present in 93.1% of heifers and 70.7% of quarters. Staph. aureus was 
isolated from teat canal keratin samples of 31% of heifers and 12.3% of quarters. Other 
organisms isolated from keratin and percentage frequencies were Staph. chromogenes (42.9%), 
Staph. hyicus (25.2%), other staphylococcal species (5.7%), Strep. dysgalactiae (0.6%), Strep. 
species (3.1%), and mixed isolates containing staphylococci and streptococci (5.7%). In this 4-
herd survey, IMI were found in 96.9% of heifers and in 74.6% of quarters. Twenty-nine 
percent of heifers and 15.1% of quarters showed clinical symptoms of mastitis as evidenced 
by clots, flakes, and blood. Staph. aureus was isolated from 14.7% of quarters. This 
microorganism was also isolated from 25% of quarters with clinical symptoms. Staph. aureus 
causes severe damage to mammary tissue (Trinidad et al., 1990a), and infections are very 
difficult to eliminate in lactating cows. Other organisms isolated from secretions and 
percentage frequencies were Staph. chromogenes (43.1%). Staph. hyicus (24.3%), other 
staphylococcal spp. (3.6%), Strep. dysgalactiae (0.4%), Strep. spp. (3.3%), Nocardia species 
(0.4%), and mixed isolates containing staphylococci and streptococci (5.1%). 
These initial studies on heifer mastitis were performed in Louisiana, USA, where a warm 
and humid climate with a long fly season may be conducive to IMI in these young dairy 
animals. Thus, a subsequent national trial was carried out using 1583 breeding age heifers 
from 28 herds to determine the prevalence of heifer mastitis in the states of California, 
Washington, and Vermont as well as in Louisiana (Fox et al., 1995). The majority of 
quarter infections were caused by the CNS (mean = 27.1%). The mean prevalence of Staph. 
aureus among the 4 sites was 2.9%, but was highest in Louisiana at 10.1% during the 
spring season. The overall IMI prevalence was greatest in Louisiana, and the highest 
frequency was during the 3rd trimester of gestation just prior to parturition, which was 
due to an increase in IMI cause d by Staph. aureus, CNS, and environmental streptococci. 
Likewise, following parturition, the greatest prevalence of IMI was in Louisiana, which 
had the greatest percentage of heifers with IMI caused by the environmental streptococci 
and Staph. aureus, and the 2nd greatest prevalence of CNS among the 4 sites. For breeding 
age and bred heifers, the stage of pregnancy significantly affected IMI prevalence, which 
was highest for heifers in the last trimester of pregnancy, especially CNS IMI. This study 
by Fox et al. (1995) showed that site location had a significant effect on prevalence of 
mastitis, and that Louisiana had the greatest prevalence of IMI. This was postulated to be 
due to the warm and humid climate, as well as to a prolonged horn fly season in 
Louisiana that exposed udders and teats to an increased bacterial load that management 
practices failed to control.  
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3. Mammary leukocyte response to intramammary infection 
In lactating cows, the milk somatic cell count (SCC) composed of leukocytes 
(macrophages, lymphocytes, neutrophils) and a small percentage of mammary epithelial 
cells, is considered an important parameter for assessing mammary health status (e.g. 
inflammation); milk yield decreases as SCC and incidence of mastitis increase. Thus, SCC 
in breeding age and pregnant heifer mammary gland secretions have been analyzed to 
measure the degree of inflammation and potential reductions in future milk yield. In a 
study by Boddie et al. (1987), the mean arithmetic SCC of quarters from unbred heifers 
infected with Staph. chromogenes, Staph. hyicus, and Staph. aureus were 7.8, 8.5, and 9.2 x 
106/ml, respectively, whereas the mean SCC of uninfected quarters was 3.5 x 106. The 
mean SCC of heifer secretions collected on the day of freshening were 3.2 x 106/ml and 1.6 
x 106/ml for quarters infected by staphylococci and uninfected quarters, respectively. The 
mean SCC during the first 3 months of lactation in quarters infected with Staph. 
chromogenes, Staph. hyicus, and Staph. aureus were 168, 193, and 578 x 103/ml, respectively, 
while the SCC of uninfected quarters was 39 x 103/ml. Thus, this study found SCC 
approaching 200 x 103 for quarters infected with CNS during the first 3 months of 
lactation, and, based on previous studies (Jones et al., 1984; Kirk, 1984), SCC in this range 
are associated with milk loss. Approximately 13% of quarter secretions sampled 
prepartum contained Staph. aureus, and after freshening, the SCC of these quarters 
averaged 578 x 103/ml, a cell count that has been associated with a loss of >4.4 lb (2.0 kg) of 
milk/day (Kirk, 1984). 
Other studies have also demonstrated elevated SCC in heifer mammary glands infected 
with mastitis-causing bacteria. For example, in a study by Trinidad et al. (1990b), average 
arithmetic SCC in secretions from 325 quarter samples regardless of infection status was 
11.7 x 106/ml. Infected (n = 240) and uninfected (n = 85) quarters had secretion SCC of 13.6 x 
106/ml and 5.7 x 106/ml, respectively. Of the staphylococci, Staph. aureus-infected quarters 
had the highest secretion SCC/ml (17.3 x 106), followed by Staph. chromogenes (12.8 x 106), 
and Staph. hyicus (12.4 x 106). The mean SCC for non-agalactiae streptococci was 15.5 x 
106/ml.  
The volume of mammary secretion is very low in breeding-age animals; thus, SCC become 
concentrated, resulting in high SCC even in uninfected quarters. However, SCC approach 20 
x 106/ml in quarters infected with Staph. aureus, and over 13.6 x 106/ml in those infected with 
the CNS and Strep. species. Such elevated SCC over a long period of time suggests that 
mammary tissue in affected quarters are in a state of chronic inflammation, which could 
adversely affect development of milk-producing tissues and negatively affect future milk 
yield. In response to infection, neutrophils become the major leukocyte type that infiltrates 
mammary tissue from the vascular system. The function of the neutrophil influx via 
chemotaxis is to phagocytose and kill mastitis-causing bacteria. But there is also evidence 
that this defense response can impair and disrupt mammary function (Akers & Thompson 
1987; Capuco et al., 1986; Zhao & Lacasse, 2008). For example, in addition to the damage 
caused by bacterial toxins, the migration of leukocytes, namely neutrophils, across the 
mammary epithelial surfaces is thought to cause mechanical damage and/or chemical 
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damage (via release of reactive oxygen species) to the milk secretory cells as well as to the 
ductal cells of the mammary gland.  
4. Histological response of the mammary gland to IMI 
Initially, the mammary glands of dairy heifers were studied to determine histological 
responses to teat canal colonization with Staph. chromogenes and Staph. hyicus (Boddie et al. 
(1987). Two unbred heifers were slaughtered, one at 8 months and the other at 18 months of 
age, and examination of mammary tissues from both heifers demonstrated a leukocyte 
reaction to the colonization of the teat canal. Cross-sections through the mid-teat canal 
demonstrated cocci colonizing keratinized cells of the canal lumen, and sections of distal 
teat cisternal tissues demonstrated heavy leukocyte infiltration with lymphocytes and 
plasma cells at Fürstenberg’s rosette compared with uninfected tissues. 
Subsequently, 7 unbred heifers, 14 - 26 months of age, were studied to evaluate the effects of 
IMI on leukocyte infiltration and characteristics of secretory tissue in developing mammary 
glands (Trinidad et al., 1990a). Histologic observations of tissue samples from lobes of 
mammary parenchyma of uninfected quarters showed that alveoli were small; the epithelial 
lining was composed of a single layer of cuboidal cells surrounding a small luminal space 
with little or no stained secretory product (See Figures 1 through 3). Interalveolar connective 
tissue area composed approximately half of the observed lobes, and a few infiltrating 
leukocytes, mainly lymphocytes, were observed. 
Infected tissues, particularly those with Staph. aureus IMI, exhibited large amounts of 
interalveolar connective tissues and reductions in epithelial and luminal areas (See Figures 
4-8). Such areas also exhibited leukocytic infiltration, particularly lymphocytes and 
neutrophils, into stromal and luminal areas. Hyperplasia of ducts and cisterns as a result of 
infection was also observed, and macro- and microscopic abscesses were found in the 
parenchyma of one quarter infected with Staph. aureus. Abscesses were tubercule-like with a 
circular, stratified fibrosis containing numerous lymphocytes, neutrophils, plasma cells, and 
multinucleated giant cells. 
Results of morphometric analysis on parenchymal tissue components showed that 
percentages of each component in uninfected quarters were very similar to percentages 
from quarters infected with CNS, although quarters infected with CNS exhibited 
significantly more stromal area. Percentages of alveolar epithelium and lumen in 
quarters infected with Staph. aureus were significantly lower (P < .05) than those in 
uninfected quarters and in quarters infected with CNS. Quarters infected with Staph. 
aureus also showed a greater percentage (P < .05) of interalveolar stroma than did 
uninfected quarters and quarters infected with CNS. Thus, Staph. aureus-infected tissue 
demonstrated reduced secretory activity. The greatest development of secretory tissue in 
young heifers occurs during the first pregnancy, and developing secretory tissues may 
be affected adversely by bacterial infection and inflammation, leading to deposition of 
connective tissue stroma instead of milk secretory tissue and a subsequent deleterious 
effect on future milk yield. 
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Figure 1. General view of a cross-section of a lobe of mammary tissue from an uninfected quarter 
exhibiting large ducts (D) and undeveloped lobules of parenchyma (P) among adipose tissue stroma. 
(A). x18.  
 
Figure 2. Portion of mammary parenchymal tissue typical of that obtained from uninfected quarters 
and those infected with coagulase-negative staphylococci exhibiting small alveoli with empty, ovoid 
lumens (1) and those with some secretions (2). x180.  
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Figure 3. Portion of uninfected parenchymal tissue revealing limited stroma (S), flattened epithelium 
(E), and distended luminal areas (L) engorged with flocculent matter suggested active secretion. x180. 
 
Figure 4. Parenchymal tissue from a quarter infected with Staph. aureus exhibiting a large interalveolar 
connective tissue stroma (S) and limited alveolar luminal areas (L). D = Duct. x180. Trinidad et al., 
1990a. 
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Figure 5. Parenchymal tissue from a quarter infected with Staphylococcus aureus showing numerous 
neutrophils (arrows) infiltrating a luminal area (L) of one alveolus. x500.  
 
Figure 6. Extensive epithelial hyperplasia (H) was observed in ductal linings in the parenchyma from 
one quarter infected with Staphylococcus aureus. Lymphoid cells (arrowheads) were numerous in the 
epithelium as well as in the underlining connective tissue. D = duct. x180.  
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Figure 7. Abscess (A) from one quarter infected with Staphylococcus aureus exhibiting tubercle-like 
morphology with circular stratified fibrosis (arrows) and marked cellular infiltration. E = Portion of 
enlarged in Figure 8. P = Parenchyma. x18.  
 
Figure 8. Magnification of an edge of the abscess shown in Figure 7. Neutrophils (arrows), 
macrophages (arrowheads), and multinucleated giant cells (MGC) were present in this area of the 
abscess. x500. Trinidad et al., 1990a. 
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Leukocyte infiltration into cisternal and parenchymal mammary tissues was also evaluated. 
Quarters infected with Staph. aureus exhibited the greatest tissue leukocytosis, followed by 
quarters infected with CNS and uninfected quarters. Leukocyte infiltration in gland cistern 
and secretory tissue for infected quarters was significantly higher (P < .05) than that for 
uninfected quarters. Leukocytosis into teat cistern tissue was similar for uninfected quarters 
and those infected with CNS, but significantly lower (P < .05) than quarters with Staph. 
aureus IMI. None of the uninfected quarters or quarters infected with CNS demonstrated 
marked leukocyte infiltration. However, marked leukocyte infiltration, particularly 
lymphocytes, into cisternal and parenchymal areas was commonly observed in quarters that 
were infected with Staph. aureus. The majority of leukocytes observed within alveolar 
lumina were neutrophils. 
5. Efficacy of nonlactating cow antibiotic therapy 
Because of the high level of infection commonly found in breeding age and pregnant heifers, 
especially mastitis caused by Staph. aureus, as well as the associated elevated SCC, 
antimicrobial therapy should be considered. The testing of various staphylococcal isolates 
obtained from heifers for susceptibility to antibiotics commonly incorporated into mastitis 
infusion tubes has shown that antibiotic resistance is usually low (Watts et al., 1995). Greater 
than 90% of mastitis-causing staphylococci are generally killed by the drug preparations 
used, based on in vitro sensitivity testing using zone diffusion analysis (Watts et al., 1995). 
From a practical standpoint, the administration of antibiotics by a parenteral route would be 
preferred; however, in the author’s experience, neither subcutaneous nor intramuscular 
injections of drugs have been found to cure IMI in heifers because sufficient antibiotic does 
not pass into the mammary gland to be bactericidal. Thus, intramammary infusion is the 
route of choice.  
In an initial study to evaluate the effectiveness of treatment, several heifers from each of the 
4 commercial herds studied by Trinidad et al. (1990c) were randomly selected to receive a 
single intramammary treatment of a penicillin and dihydrostreptomycin product. 
Antimicrobial susceptibility testing demonstrated that 97% of the Staph. aureus isolates were 
sensitive to 12 antibiotics, including the product selected for treatment (Trinidad et al., 
1990d). Teat ends were sanitized, and a dry cow antibiotic containing 1,000,000 units of 
penicillin and 1 gram of dihydrostreptomycin was infused into all quarters of 35 heifers 
using the partial insertion technique; 38 heifers served as untreated controls. Treatments 
were made at approximately 60 days prior to the calculated calving date. 
Results showed that 97.1% of treated heifers (73.2% of quarters) were infected at the time of 
treatment, but, at calving, infected heifers and quarters in the treatment group were reduced 
to 40 and 34%, respectively. Antibiotic residues were limited to two heifers that were treated 
within 3 weeks of calving because estimated dates of parturition were miscalculated, but all 
quarters were free of antibiotic residue after 5 days; 2.9% of treated quarters had antibiotic 
residues at time of calving. Of the 38 untreated control heifers, 100% (71.2% of quarters) 
were infected at initial sampling, and at calving, mastitis in control heifers was reduced only 
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slightly to 97.4%; percentage of infected quarters increased slightly to 77.8%. The mean SCC 
at calving was also reduced as a result of therapy. For treated heifers, SCC decreased 
significantly (P < .001) from 11,825 x 103/ml at time of treatment to 3,439 x 103/ml at calving. 
In the control group, SCC decreased from 11,047 x 103/ml to 5,594 x 103/ml (P > .05, not 
significant). 
In the same study, Staph. aureus was isolated from 11 quarters of 6 treated heifers before 
antibiotic infusion (45.8%), but, at calving, this organism was isolated from only 1 quarter of 
1 heifer (4.2%). In the control group, 18 quarters of 10 heifers were infected with Staph. 
aureus at time of treatment (45%). At calving, 6 of the control heifers still had Staph. aureus 
mastitis in 11 quarters (55%). Thus, the overall incidence of IMI was reduced 60% and that 
caused by Staph. aureus was reduced over 90%. From 20 to 26% of quarters with subclinical 
and clinical Staph. aureus mastitis are typically cured after antibiotic therapy (Dodd, 1992). In 
this study, 90.9% of quarters were cured; thus, therapy in heifers was highly effective in 
eliminating S. aureus mastitis compared with that for lactating cows. 
In this study, an economic analysis was performed to justify use of the heifer treatment 
program (Trinidad et al., 1990c). Production data collected over the first 2 months of 
lactation demonstrated that Staph. aureus-infected heifers receiving nonlactating cow 
therapy during pregnancy produced an average of 5.5 pounds (2.5 kg) more milk per day 
than Staph. aureus-infected herd mates that did not receive treatment. At the milk price 
received at that time, the greater milk yield translated to a $42.00 increase for treated heifers, 
which was well worth the $5.00 cost of treatment. Other advantages include a longer 
productive life and higher income due to quality milk premiums. 
Subsequent studies (Owens et al., 1991, 1994) with pregnant and nonpregnant heifers using 
a cephalosporin-based product formulated for nonlactating cows was also successful. 
Heifers that were either experimentally or naturally infected with Staph. aureus were infused 
8 -12 weeks prepartum with one dose of 300 mg of a cephapirin benzathine product and 
were compared with untreated controls infected with Staph. aureus. Results demonstrated 
that 100% of experimentally induced IMI and 87% of naturally occurring Staph. aureus IMI 
were eliminated in treated heifers at calving, and cured quarters remained negative at 
biweekly samples collected 2 months into lactation. Quarters remaining infected at calving 
with Staph. aureus were treated with a lactating cow product containing 200 mg of 
cephapirin benzathine, but the cure rate was lower (50 - 56%). Thus, cure rates were greater 
when a nonlactating product was administered 8 -12 weeks prepartum than when a 
lactating cow product was given at time of calving. 
After antibiotic infusion, SCC in infected quarters that cured decreased from 15 x 106/ml 
to 4 x 106/ml 1 week later, and to 700 x 103/ml at calving. In contrast, none of the untreated 
control quarters infected with Staph. aureus cured spontaneously by the time heifers 
calved, and SCC at calving were 5 x 106/ml. Treated heifers in which Staph. aureus IMI 
were cured yielded a mean of 36.1 lb (16.4 kg) milk/day, and untreated controls that 
retained Staph. aureus IMI yielded 31.9 lb (14.5 kg)/day or 11% less during the first 2 
months of lactation. 
 
Milk Production – An Up-to-Date Overview of Animal Nutrition, Management and Health 344 
Generally, spontaneous cure rates for major mastitis pathogens are low. For example, in a 
subsequent study on heifer mastitis (Owens et al., 1994), spontaneous cure rates for Staph. 
aureus and the environmental streptococci were 9 and 6%, respectively. Thus, treatment is 
required to cure such infected quarters in these young dairy heifers. New IMI rates in 
uninfected quarters receiving no therapy over the period from 8 - 10 weeks prepartum were 
very low for most species of staphylococci. However, new environmental streptococcal IMI 
were common in previously uninfected, untreated heifers. So, as part of this study (Owens 
et al., 1994), a trial was initiated to treat quarters found to be negative at 8 – 10 weeks 
prepartum with cephapirin benzathine to determine if establishment of new environmental 
streptococcal IMI could be prevented during this 8 – 12 week prepartum period. Results 
showed that prophylactic treatment of such quarters prepartum reduced new 
environmental streptococcal IMI at calving by 93%. Thus, in this trial, use of nonlactating 
cow therapy was effective in preventing new IMI as well as curing existing infections. 
Reasons for this high cure rate are unclear, but the relatively small secretory tissue area of 
heifer mammary glands compared with mature cows might allow for greater drug 
concentrations in the udder of the heifer. Similarly, histological studies have demonstrated 
less scar tissue and abscess formation in the mammary glands of heifers compared with 
older cows (Trinidad et al., 1990a), a condition which would allow for better drug 
distribution and greater contact with colonized bacteria.  
6. The optimum treatment schedule for maximizing efficacy of 
nonlactating cow therapy 
The question arises as to when is the best time to treat bred heifers for optimizing cures 
against Staph. aureus mastitis. A 2-year study involving 233 Jersey heifers was designed to 
answer this question (Owens et al., 2001). In this trial, heifers were quarter sampled shortly 
after they were confirmed pregnant and at 4-week intervals thereafter. At the initial 
sampling, 56.5% of quarters were infected with some type of organism, and 15.4% of 
quarters were infected with Staph. aureus. After the initial sampling, animals were treated 
with a one-time infusion of 1 of 5 nonlactating cow infusion products during the first (0 - 90 
days), second (91 - 180 days), or third (181 - 270 days) trimester of pregnancy. Products 
evaluated were: 1) a combination of 1 million units of penicillin and 1 gm 
dihydrostreptomycin; 2) 300 mg cephapirin benzathine; 3) a combination of 400 mg 
novobiocin and 200,000 units of penicillin G; 4) 300 mg tilmicosin; and 5) 250 mg 
cephalonium (this last product was only infused during the first trimester of gestation). 
Results showed that cure rates for the 5 products were high, ranging from 67 to 100%, and 
significantly higher than the spontaneous cure rate (25%) observed in untreated control 
quarters. No differences were observed among the three treatment time periods during 
gestation. However, fewer new Staph. aureus infections occurred after treatment in the group 
infused during the 3rd trimester, indicating that treatment during this time will reduce 
incidence of new IMI after infusion and continuing to calving. Because therapy during the 
first, second, or third trimester of gestation had no effect on treatment efficacy, the timing of 
treatment is best determined by what is most convenient for the management practices of a 
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particular dairy. For example, heifers could be treated: 1) at time of artificial insemination; 2) 
during routine rectal palpation to determine pregnancy status; or 3) when moved to a new 
location in preparation for calving. Treatment should be administered no less than 45 days 
prior to expected calving date to prevent antibiotic residues at calving. 
Sampimon & Sol (2005) studied the efficacy of nonlactating cow therapy (600 mg cloxacillin) 
administered intramammarily 8-10 weeks prepartum in 1) 5 low prevalence farms in which 
less than 15% of heifers had SCC of >150,000/ml at the beginning of the trial, and 2) 8 high 
prevalence farms in which greater than 15% of heifers had SCC of >150,000/ml at the 
beginning of the trial. Results showed that in high prevalence farms, treated heifers 
produced significantly more milk during the first 100 days of lactation compared with 
untreated controls; however, in low prevalence farms, treatment had no effect on 
production. In both groups of farms, SCC and incidence of clinical mastitis were 
significantly lower in heifers receiving antibiotic therapy. Authors concluded that 
nonlactating cow therapy was beneficial in high prevalence farms, but not in low prevalence 
farms. 
The treatment of heifers during pregnancy with a nonlactating cow product is advantageous 
because: 1) the cure rate is higher than during lactation, especially against Staph. aureus; 2) 
there are no milk losses during therapy; 3) the risk of antibiotic residues is minimal; 4) SCC 
at calving is reduced; 5) new IMI with environmental streptococci is prevented; and 6) milk 
production is increased by approximately 10% in successfully treated animals in some 
herds.  
7. Efficacy of parenteral antibiotic treatment and an infusible teat seal in 
curing and preventing IMI  
In one study involving 1,067 pregnant heifers in 30 New Zealand herds (McDougal et al., 
2005), mammary quarters were treated 1 month prepartum with 1) an infusible teat seal 
composed of bismuth subnitrate; 2) parenteral administration of antibiotic via injection of 5 
gm of tylosin i.m. daily for 3 days; 3) teat seal plus tylosin; or 4) no treatment in order to 
determine if treatment reduced the prevalence of IMI and incidence of clinical mastitis 
postpartum. Results demonstrated that heifers treated prepartum with teat seal exhibited a 
reduced prevalence of IMI as well as reduced incidence of clinical mastitis. However, 
treatment with tylosin prepartum did not reduce prevalence of mastitis or incidence of 
clinical mastitis postpartum.  
8. Efficacy of lactating cow products in curing IMI  
Lactating cow products have been used successfully in heifers when treating infections 
caused by the environmental streptococci and CNS immediately prior to calving. Studies on 
this subject are typically performed on heifers in late gestation 2 - 3 weeks before calving. In 
an initial study conducted at the University of Tennessee, quarters of 115 pregnant Jersey 
heifers were infused one time at approximately 1 week prepartum with either 200 mg 
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sodium cloxacillin, 200 mg cephapirin sodium, or left untreated (Oliver et al., 1992). At the 
time of infusion, approximately 90% of heifers were infected in one or more quarters. For 
heifers left untreated, 78% of animals (44.5% of quarters) remained infected at time of 
calving. However, only 17.6% of the heifers (4.5% of quarters) remained infected at calving if 
they were treated prepartum, regardless of the product used. Results demonstrated that 
significantly fewer antibiotic treated heifers and quarters were infected at calving compared 
with untreated controls. This study also examined the influence of prepartum antibiotic 
treatment on subsequent lactational performance, and demonstrated that heifers receiving 
treatment produced approximately 1,000 lb (455 kg) more milk per lactation than untreated 
controls. 
Mastitis pathogens were isolated from 76% of untreated control quarters at 7 days before 
calving, from 47% of samples at 3 days after calving, and from 29% of samples at 10 days 
postpartum. Throughout the remainder of lactation, pathogens were isolated from 30% of 
control quarters. A similar percentage of samples (70%) was positive for mastitis pathogens 
at 7 days before calving in antibiotic-treated quarters; however, only 8% of samples obtained 
at 3 days after calving and 4% of samples obtained 10 days postpartum contained 
pathogens; throughout the remainder of lactation, mastitis pathogens were isolated from 
only 11% of quarters. Strep. uberis, Strep. dysgalactiae, and CNS species were isolated most 
frequently in both untreated controls and antibiotic-treated heifer mammary glands. 
In a subsequent study reported by Oliver et al. (1997b), mastitis pathogens were isolated 
from 67% of samples obtained from control mammary glands (quarters to be left untreated) 
14 days prior to expected calving, from 56% of samples obtained 3 days after calving, and 
from 36% of samples obtained 30 days postpartum; throughout the remainder of lactation, 
mastitis pathogens were isolated from 45% of quarters. In quarters to be treated with 200 mg 
cephapirin sodium, 64% were positive for mastitis pathogens prior to antibiotic treatment; 
however, only 16% of samples obtained at 3 days after calving and 8% of samples obtained 
30 days postpartum contained pathogens. Throughout the remainder of lactation, mastitis 
pathogens were isolated from an average of 12% of quarters. Coagulase-negative 
staphylococci were isolated most frequently followed by environmental mastitis pathogens.  
A follow-up study was conducted to determine if prepartum therapy with penicillin-
novobiocin or pirlimycin hydrochloride was effective in reducing the percentage of infection 
with mastitis pathogens during early lactation (Oliver et al., 2004). Almost 73% of Holstein 
heifers (34.3% of quarters) were infected 14 days before expected calving. Of the quarters 
infected 14 days before parturition, 76% were uninfected following treatment with 
penicillin-novobiocin, 59% were uninfected following treatment with pirlimycin, and 26% 
were uninfected in the untreated control group. The majority of IMI were due to CNS (44%) 
and Staph. aureus (30%). 
Among the Jersey heifers, 96% of animals and 71.3% of quarters were infected 14 days 
before calving. Of the quarters infected at 14 days before parturition, 75% were uninfected 
following treatment with penicillin-novobiocin, 87% were uninfected following treatment 
with pirlimycin, and 56% were uninfected in the untreated control group. The majority of 
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IMI were due to CNS (61%), Strep. spp. (19%), and Staph. aureus (8%). Thus, prepartum 
therapy of heifer mammary glands with penicillin-novobiocin or pirlimycin hydrochloride 
was effective in reducing the percentage of heifers and quarters infected with mastitis 
pathogens during early lactation. 
As a part of the University of Tennessee studies, milk production and somatic cell score data 
from 82 control heifers and 111 heifers treated with antibiotics before calving were 
evaluated (Oliver et al., 2003). Milk production (actual and 305-day) was significantly higher 
in heifers treated prepartum with antibiotics. Additionally, treated heifers had a 
significantly lower somatic cell scores than control heifers (2.04 vs. 2.63). Thus, prepartum 
antibiotic treatment to reduce the rate of mastitis in heifers during early lactation was 
economically beneficial. Treated heifers produced 1,168 lb (531kg) more actual milk than the 
untreated controls. Based on a milk price of $18.50/cwt this resulted in $216.24 per heifer 
increase in gross revenue. Considering treatment costs of $15.60 per heifer including teat 
hygiene ($0.10), antibiotic ($10.00), labor ($2.50), and residue testing ($3.00), the net revenue 
amounted to $200.64 per heifer. The researchers concluded that it would be profitable to 
treat heifers before calving as long as the milk price was above $0.013 per pound and as long 
as the increase in milk production was greater than 84 pounds (Oliver et al., 2003). 
Middleton et al. (2005) also evaluated the prepartum treatment of heifers with pirlimycin 
hydrochloride at 10-14 days before parturition on the prevalence of IMI at calving in 2 dairy 
farms. Postpartum sampling revealed that heifers receiving treatment in herd A had a 
higher overall cure rate and higher cure rates for IMI caused by CNS and Staph. aureus as 
well as lower SCC and lower prevalence of chronic IMI compared with untreated controls. 
The cure rate for Staph. aureus of 78% was significantly greater than that for untreated 
controls (8%). Treated heifers in herd B had a higher overall cure rate and higher cure rate 
for IMI caused by CNS compared with untreated controls, but CMT (SCC) scores and 
prevalence of chronic IMI were not different. In contrast to previous results of using 
lactating cow therapy, (Oliver et al., 2003), milk production did not differ between treatment 
groups. Authors concluded that routine prepartum therapy of heifers may not benefit all 
herds. 
Subsequently, Borm et al. (2006) evaluated the efficacy of lactating cow intramammary 
therapy (cephapirin) administered to heifers 10-21 days prior to expected calving date in a 9-
herd study involving 561 animals. Results demonstrated a 59.5% cure rate among mammary 
quarters that were infected prepartum and treated with antibiotic vs. untreated controls 
(31.7%). However, treatment did not significantly affect SCC or milk yield during the first 
200 days of lactation. This observation is similar to that found by Middleton et al. (2005) 
who observed that although successful, treatment did not necessary reduce SCC or result in 
greater milk production. Authors concluded that prepartum treatment of heifers with 
lactating cow antibiotics may not be warranted as a universal strategy for mastitis 
management. 
The studies on prepartum treatment with lactating cow therapy administered 7 - 21 days 
before calving (Borm et al., 2006; Oliver et al., 1992, 1997b, 2003, 2004) have shown treatment 
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to be effective for quarters infected with CNS but waiting until this time to treat chronic 
Staph. aureus mastitis might be too late. A mammary gland that has been infected with Staph. 
aureus for several months to a year will not develop normally, and treatment during the 
immediate prepartum period would most likely be of little benefit in curing infections or 
salvaging mammary tissue. At this point, the tissue damage would have already been done, 
and affected quarters should have been treated earlier in gestation to: 1) cure existing 
infections; 2) reduce chronic inflammation; and 3) allow mammary tissue to develop 
normally during the later stages of pregnancy. 
Results of these trials demonstrated that nonlactating and lactating cow antimicrobial 
treatment of heifers known to be at risk for developing IMI is advantageous because the 
cure rate is much higher than that obtained when treating infections during lactation. In 
addition, most studies showed that SCC are lower, there is no milk loss due to therapy , risk 
of antibiotic residue at calving is minimal, and future milk production is increased in heifers 
cured of IMI. 
9. Antibiotic residues in milk following prepartum lactating cow 
treatment 
A disadvantage of prepartum lactating cow antibiotic therapy for controlling mastitis in 
heifers is the potential for antibiotic residues, especially if heifers calve sooner than 
expected. In one study (Oliver et al., 1992), it was shown that 17% of colostrum samples 
from heifer mammary glands infused with cloxacillin were positive for antibiotic residues 
by the Bacillus stearothermophilus disc assay, the majority of which were from heifers that 
calved within 5 days of treatment. Only 4.5% of samples obtained at the first milking after 
parturition were positive for antibiotic residues if intramammary infusion of cloxacillin 
occurred > 7 days before parturition. All samples obtained 3 days after parturition, the time 
when milk would likely be marketed for human consumption, were negative for antibiotic 
residues. In contrast, 85% of colostrum samples and 28.2% of samples obtained 3 days after 
parturition were positive for cephapirin residues, and marked variability between time of 
antibiotic treatment and parturition with persistence of antibiotic residues was observed. 
Thus, antibiotic treatment of heifer mammary glands earlier in gestation may be 
advantageous from a residue standpoint, but the timing of antibiotic treatment and 
subsequent persistence in mammary secretions could impact efficacy. 
Another study was conducted to determine if antibiotic treatment of heifer mammary 
glands earlier in the prepartum period reduced occurrence of residues in milk (Oliver et al., 
1997a). A total of 82 Jersey heifers was used. Approximately half served as negative controls 
(n = 42) and half received an intramammary infusion of 200 mg cephapirin sodium (n = 40) 
14 days before calving. Forty percent of samples from cephapirin-treated quarters were 
positive at the first milking after calving, but only 3.1% of samples obtained from antibiotic-
treated quarters at the sixth milking (3 days) after calving were positive; 3 of the 4 positive 
samples were from a heifer that calved early and within 3 days of treatment.  
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Thus, the interval between prepartum antibiotic treatment and calving was related to 
persistence of residues during early lactation, and infusion of antibiotics 14 days prepartum 
(Oliver et al., 1992) compared with 7 days prepartum (Oliver et al., 1997a) reduced 
occurrence of residues in milk during early lactation. Similarly, Middleton et al. (2005) 
found that after heifers were treated 10-14 days prior to expected calving date with a 
pirlimycin lactating cow product, prevalence of IMI in early lactation was decreased without 
causing pirlimycin residues in milk at 3 days postpartum, even when a heifer was treated 1 
day before calving (heifer calved early). 
10. Role of vaccination in mastitis control 
Although antimicrobial therapy is successful, the goal from a herd management perspective 
is to prevent new infections from occurring, and vaccination has been attempted as a 
prophylactic measure. Recent research has demonstrated that several experimental Staph. 
aureus vaccines, as well as one commercial vaccine, can increase antistaphylococcal antibody 
titers and reduce the new infection rate in heifers. A Staph. aureus vaccine formulated to 
stimulate pseudocapsule and alpha toxin antibodies was evaluated in heifers in New York 
(Sears et al., 1990). At 4 and 2 weeks prior to calving, heifers were given subcutaneous 
injections into the supramammary lymph node, and after calving, heifers were challenged 
with Staph. aureus. Vaccinates demonstrated a 52% reduction in new IMI. In addition, 64% of 
intramammary infections in control cows became chronic compared with only 12% in 
vaccinates.  
A field study in Norway evaluated a Staph. aureus vaccine that contained two strains of 
whole, formalin-inactivated bacteria with pseudocapsule, alpha and beta toxoids, and 
mineral oil as an adjuvant (Nordhaug et al., 1994). A total of 108 pregnant heifers on 16 
farms with an average Staph. aureus prevalence of 19.2% was used. Vaccinates were injected 
subcutaneously in the area of the supramammary lymph node with a dose of 2.5 ml at 8 and 
2 weeks before calving. Results showed a 46% reduction in new IMI during the subsequent 
lactation. Antibody titers to Staph. aureus pseudocapsule and alpha toxin were markedly 
elevated in the serum of vaccinates, and these titers remained significantly higher in serum 
and milk during the entire lactation compared with those of unvaccinated controls. 
In Argentina, a vaccine was developed based on an inactivated, encapsulated Staph. aureus 
strain, a crude extract of Staph. aureus exopolysaccharides, and inactivated, unencapsulated 
Staph. aureus and Streptococcus species in an aluminum hydroxide adjuvant (Giraudo et al., 
1997). This formulation was evaluated in three groups of ten 24- to 26-month-old heifers 
each in a 7-month trial. The first group received an intramuscular injection of the vaccine in 
the neck at 8 and 4 weeks prepartum, the second group was vaccinated similarly at 1 and 5 
weeks postpartum, and a third group (control) received placebo injections at 8 and 4 weeks 
prepartum. The research herd from which the heifers were selected had a bulk tank SCC 
ranging from 480,000 to 730,000, and 19% of quarters were infected with Staphylococcus 
aureus. This immunization program showed that the frequency of new Staph. aureus 
infection was reduced from 18.8% in controls to 6.7 and 6.0% for heifers vaccinated 
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prepartum and postpartum, respectively; the protective effect was maintained for at least 6 
months.  
In view of more recent studies showing success of vaccines in heifers, researchers in 
Louisiana evaluated a commercially available Staph. aureus vaccine in young dairy animals 
(Nickerson et al., 1999). The vaccine was a lysed culture of polyvalent Staph. aureus somatic 
antigens representing 5 phage types in an aluminum hydroxide adjuvant base, including 
serotypes 5, 8, and 336, the most common Staph. aureus serotypes associated with clinical 
mastitis (Lysigin®, Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO, USA). At 6 
months of age, 35 Jersey heifers were vaccinated using a 5-ml dose intramuscularly in the 
semimembranosus muscle of the rear leg, and 14 days later, vaccinates received a booster 
dose, which was repeated at 6-month intervals. Another 35 heifers served as unvaccinated 
controls. Results demonstrated that: (1) the number of quarters exhibiting chronic 
intramammary infection during pregnancy was reduced 43.1% in vaccinates compared with 
controls; (2) rate of new intramammary infection during pregnancy was reduced 44.8%; (3) 
rate of new intramammary infection at freshening was reduced 44.7%; and (4) the SCC was 
reduced by 50% in vaccinates compared with controls. 
In a subsequent, more in depth study using the same vaccine (Lysigin®), 106 Holstein heifers 
from the James River Correctional Center dairy herd Goochland, VA, USA were evaluated 
(Nickerson et al., 2009). This herd had a 9,979-kg rolling herd average milk production with 
an average SCC of ~200,000/ml. Previous microbiological culture of heifer mammary 
secretions indicated that approximately 35% of animals were infected with Staph. aureus.  
At approximately 6 to 18 months of age, heifers were processed through a restraining chute 
to collect aseptic quarter mammary secretion samples for microbiological. Fifty-three heifers 
were vaccinated using a dose of 5 ml intramuscularly that was administered as above, and 
the other 53 heifers served as unvaccinated controls. Fourteen days after the initial 
processing, the vaccinated group was again processed through the chute and boosted with 
Lysigin®. All animals were maintained on pasture and rotated by age group through 
calving. At 6-month intervals after the initiation of the trial and through time of calving, the 
vaccinated group was again processed through the chute for boosting.  
At 2-month intervals after the trial initiation and through calving, mammary secretion 
samples were collected for bacteriological culture and for the determination of electronic 
SCC (A/SN Foss, Hillerod, Denmark). Microbiological examination of quarter samples 
collected from bred heifers over gestation demonstrated that 19.8% of heifers (9.4% of 
quarters) were infected with Staph. aureus, 68.9% of heifers (34.3% of quarters) were infected 
with CNS, 6.6% of heifers (2.3% of quarters) were infected with environmental streptococci, 
and 1% of heifers (0.3% of quarters) were infected with coliforms. 
At time of calving, heifers were enrolled in the Dairy Herd Improvement Program (DHIA) 
and data were recorded for milk yield, percentages and actual pounds fat and protein, days 
in milk, and SCC. Data on vaccine efficacy were examined in terms of mean percentage 
reduction in rate of new Staph. aureus or CNS intramammary infections achieved among 
immunized heifers compared with the rate among unimmunized controls at the time of 
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calving; differences between the percentage of heifers becoming infected among treatments 
was tested with the standard normal approximation. 
Immunization with Lysigin® did not cause any adverse reactions at the injection site or 
systemically. Minimal swelling (<2.5 cm) was occasionally observed, which disappeared 
within 48 hours of administration. Vaccine efficacy data showed that the percentage of 
heifers with Staph. aureus intramammary infections at freshening was lower in vaccinates 
(13.3%) compared with controls (34.0%); a reduction of 60.9% (P < 0.01). Likewise, an 
examination of health records showed that the percentage of heifers that were culled or died 
during the trial was reduced by approximately one-third by vaccination: 16.9% in vaccinates 
and 24.5% in controls (P > 0.05). The vaccinated group also experienced a slight, insignificant 
reduction in mastitis caused by CNS. At freshening, intramammary infections with CNS 
were lower in vaccinates (64.2%) compared with controls (69.8%); a reduction of 8.1%. 
Somatic cell counts in samples collected during first week of lactation irrespective of 
infection status were 45% lower in vaccinates compared with controls (287,317 vs. 
522,345/ml). Somatic cell counts in samples collected during first week of lactation from 
uninfected heifers for vaccinates and controls were 66,095 and 132,754/ml, respectively; a 
50.2% reduction; and for infected heifers, SCC were 441,764 and 892,176/ml, respectively; a 
50.5% reduction. Somatic cell counts in samples collected during the prepartum period were 
highest for Staph. aureus (6,730 x 103), followed by the environmental streptococci (3,850 x 
103), and CNS (3,510 x 103). 
An examination of the 305-day lactation milk yield for the 1st lactation of both vaccinated 
and unvaccinated control heifers demonstrated an approximate 8.6% increase in vaccinates 
vs. controls (11,217 vs. 10,332 kg, respectively) or a difference of 886 kg. On a complete 
lactation basis, vaccinated animals produced 839 kg more milk than controls (12,537 vs. 
11,698 kg, respectively); an increase of 7.3%.  
The percentage of 305-day lactation fat was higher in vaccinates than controls (3.64 vs. 
3.27%, respectively); however, the percentage of 305-day lactation protein was slightly 
higher in controls than vaccinates (3.06 vs. 2.95, respectively). Actual 305-day kilograms of 
both fat and protein were higher in vaccinates than controls (fat: 408 vs. 339 kg, respectively; 
protein: 330 vs. 315 kg, respectively). Likewise, on a complete lactation basis, actual 
kilograms of both fat and protein were higher in vaccinates than controls (fat: 460 vs. 393, 
respectively; protein: 370 vs. 353, respectively). 
An examination of the number of days in milk for the first lactation demonstrated that 
vaccinates persisted 13 days longer than the unvaccinated controls (349 vs. 336 days). In 
addition, average first lactation SCC were 11,000 cells/ml lower in vaccinates compared with 
controls (49,000 vs. 60,000/ml).  
Results of this Virginia investigation demonstrated that vaccinating dairy heifers according 
to the prescribed protocol with a commercial USDA licensed Staph. aureus bacterin, Lysigin®, 
reduced the number of new Staph. aureus intramammary infections at time of calving by 
60.9%, lowered the SCC by 50%, and decreased the culling rate by approximately one-third. 
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In addition, overall milk yield, production of fat and protein, and number of days in milk 
were greater in vaccinated heifers compared with controls.  
The decrease in frequency of new Staph. aureus intramammary infections at calving (60.9%) in 
vaccinates using Holstein heifers is higher than the 44.7% reduction observed in a Louisiana 
trial using the same vaccine in Jersey heifers (Nickerson et al., 1999). In both trials, SCC at 
calving were reduced by approximately 50%. The 60.9% efficacy found in the present trial is 
also higher than the 40.2% efficacy observed by Giraudo et al. (1989), the 46% efficacy 
observed by Nordhaug et al. (1994), and the 52% efficacy observed by Sears et al. (1990). 
However, it is difficult to compare among the latter three trials as the vaccine formulations 
were all quite different.  
The question becomes: Is it economically feasible to use this commercial vaccination 
protocol on young dairy heifers? Based on an average of 1,864 more lb milk per vaccinated 
heifer, which translates to 18.64 hundredweights (cwt) of milk (1,864/100), at the current 
(2008) price of $25.00/cwt, an increased income of $466.00/heifer would be realized (18.64 
cwt x $25.00/cwt = $466.00). If each heifer was vaccinated beginning at 6 months of age until 
calving, this would entail vaccinations at 1) 6 months, 2) a booster 2-weeks later, and 
subsequently at 3) 12 months, 4)18 months, and 5) 24 months, or a total of 5 immunizations 
through calving. At $1.50/dose, this cost would total $7.50, which when subtracted from the 
increased income from milk production, would yield a net income of $458.50 per heifer 
($466.00 - $7.50). This figure does not include the costs of labor involved in the 
immunization process; however, it is evident that vaccination is well worth the cost of the 
vaccine. Not only does it reduce new infections in first calf heifers at parturition, it may also 
reduce the introduction of Staph. aureus to the milking herd.  
It is obvious that use of experimental and commercially available Staph. aureus vaccines can 
be used to prevent new infections, especially when used in heifers. Efficacy has been shown 
to range between 44 to 61% with reductions in SCC of 50%. This prevention strategy may 
represent a major control mechanism for managing Staph. aureus in the future, especially as 
new antigens and adjuvants are added to vaccine preparations. 
11. Use of fly control to manage heifer mastitis  
Historically, the major association between flies and intramammary infections has been with 
the development of summer mastitis, in which the biting fly, Hydrotoea irritans, is the proven 
vector (Chirico et al., 1997). Summer mastitis is an isolated seasonal problem primarily in 
July, August, and September in heifers and dry cows of northern Europe, and may be 
controlled by insecticidal sprays. In the US, fly control is used to reduce these insect pests on 
farm premises, and subsequently reduce animal stress, but its application as an adjunct 
management practice for preventing new cases of mastitis and reducing SCC has not really 
been considered or embraced by producers.  
Surprisingly, very little research has been conducted on the relationship between mastitis in 
adult cows and fly control; most studies in this regard have been carried out in dairy heifers. 
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An initial survey performed at Louisiana State University showed that prevalence of 
mastitis in bred heifers was significantly lower in dairy herds that used some form of fly 
control for their lactating cows, dry cows, and heifers compared with herds applying no fly 
control (Figure 9) (Nickerson et al., 1995). The greatest reductions were in numbers of Staph. 
aureus and the environmental streptococci, both major mastitis pathogens in adult cows 
associated with elevations in SCC.  
Results of this survey also demonstrated that bred heifers having teats with bite lesions and 
scabs caused by the blood-sucking horn fly (Haematobia irritans), exhibited a 70% frequency 
of intramammary infection compared with a 40% frequency in heifers with normal teats. 
Such infections are always associated with elevated SCC in excess of 5 million/ml in these 
young animals. See Figure 10 below illustrating horn flies and lesions on heifer teats. 
 
Figure 9. Prevalence of mastitis in Louisiana dairy herds with and without a fly control program.  
Since that first survey, researchers have proven through DNA studies that the horn fly is not 
only responsible for teat lesions on heifers, but is indeed a vector in the transmission of 
mastitis-causing bacteria, such as Staph. aureus, from heifer to heifer (Owens et al., 1998). 
Such mastitic heifers serve as sources of IMI for transmission to the entire lactating and 
nonlactating herds.  
Once it was established that the horn fly was a vector in the transmission of mastitis-causing 
bacteria, the next step was to develop management practices to reduce flies and lower the 
prevalence of intramammary infections. Insecticide-impregnated tags placed on the tail 
switch in close proximity to the udder during the spring and summer months were 
successful in reducing horn fly populations by 60% as well as the incidence of mastitis 
during the first 2 months after placement (Nickerson et al, 1997). In heifers with tail tags, 
mastitis incidence increased from 8.6 to 15% (1.7-fold increase), while in controls, incidence 
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increased from 17.1 to 52.4% (3.1-fold increase). As observed above, infections were 
associated with marked elevations in SCC. However, after 2 months, tags fell off and 
replacing them was impractical from a management standpoint.  
 
Figure 10. Udder of a 10-month-old heifer illustrating horn flies and lesions on teat ends. 
In a subsequent trial, the daily dietary supplementation of an insect growth regulator helped 
to suppress fly populations but not enough to prevent new cases of mastitis in dairy heifers 
(Owens et al., 2000).  
Lastly, the use of an insecticidal pour-on every 2 wk for 6 wk followed by treatment with 
insecticidal ear tags reduced fly populations and decreased the incidence of new Staph. aureus 
by 83% during a 6-mo trial in heifers during the warm season in Louisiana (Owens et al., 2002). 
Mastitis in heifers caused by Staph. aureus was associated with SCC in excess of 10 million/ml. 
These studies demonstrate that, during the warm and humid months of the year, horn flies 
do serve as vectors in the transmission of heifer mastitis, which is associated with elevated 
SCC in these young dairy animals. Although research has not been conducted to show this 
same association in lactating and dry adult cows, it is assumed that fly populations play 
some role in the elevation of mastitis and SCC observed in the hot summer months. And, 
with the proposed reduction in the SCC legal limit to 400,000/ml in the USA, and in light of 
the fact that milk buyers are imposing their own limits, some as low as 250,000/ml, it is 
imperative that dairymen utilize all possible means to prevent new cases of mastitis and 
their associated SCC. A simple fly control program can serve as an important adjunct to the 
basic 5-point plan of mastitis control and assist dairymen in lowering their bulk tank SCC 
and earn quality premiums for their product.  
 
Managing Mastitis in Heifers: An Initial Step in Improving Dairy Herd Health 355 
12. Influence of dietary supplementation on mammary health 
Another management tool to reduce the level of infection and SCC when heifers calve as well as 
throughout lactation is through dietary supplementation. Diet plays a role in udder resistance 
to infection because certain nutrients affect various mammary resistance mechanisms, namely: 
(1) leukocyte function, (2) antibody transport, and (3) mammary tissue integrity. In one study, 
heifers received selenium (0.3 ppm/day) and vitamin E (50 to 100 ppm/day) supplementation 
starting 60 days prepartum (Hogan et al., 1993). A selenium booster injection (50 mg) was 
administered 21 days prior to freshening, and the dietary supplementation was continued 
throughout lactation. Dietary supplementation reduced staphylococcal and coliform infections 
at calving by 42%. Although rate of new infection during lactation did not differ from 
unsupplemented controls, the duration of infection caused by organisms other than 
Corynebacterium bovis was reduced 40 to 50% in supplemented heifers. Clinical mastitis in 
supplemented heifers was reduced 57% in early lactation and 3.2% throughout lactation, and 
the mean SCC was lower. Thus, vitamin E and selenium improved udder health of heifers, and 
the effect of dietary supplementation was most evident at calving and in early lactation. 
In a more recent study, dairy heifers were fed a daily supplement beginning at 5 months of 
age containing an immunostimulant composed of B-complex vitamins and yeast extract 
(Eubanks et al., 2011). Compared with unsupplemented control animals, those 
supplemented with the immunostimulant exhibited greater leukocyte expression of L-
selectin and interleukin-8 cell surface receptors, suggesting the capability for a greater 
immune response to bacterial infection. Preliminary results also showed a lower incidence 
of Staph. aureus mastitis in supplemented heifers.  
13. Conclusions  
Prevalence of mastitis in unbred, breeding age, and pregnant dairy heifers is higher than 
formerly realized. Infected mammary quarters, especially those with Staph. aureus IMI exhibit 
reduced secretory potential and marked leukocyte infiltration and accompanying 
inflammation. Both nonlactating and lactating commercial antibiotic infusion products have 
been used successfully to cure existing infections and reduce SCC, and nonlactating therapy 
prevents new IMI with environmental streptococci. However, the goal is to prevent new 
infections from occurring in these young dairy animals through management strategies 
aimed at vaccination, fly control, and dietary supplementation. Results of experimental and 
commercial vaccine trials illustrate that immunization will reduce Staph. aureus mastitis in 
heifers at calving between approximately 45 and 60%, with reductions in SCC of 50%. 
Likewise, a fly control program for heifers will decrease incidence of Staph. aureus mastitis by 
up to 83%. Lastly, dietary supplementation to boost the immune systems of heifers has been 
shown to reduce incidence of mastitis at calving as well as to lower SCC. As global milk 
quality standards become more stringent, management practices based on curing existing 
infections and preventing new IMI in heifers will ensure that these young dairy animals enter 
the milking herd free of mastitis with low SCC. Such practices should be considered for 
incorporation into dairy herd health programs in herds suffering from a high prevalence of 
heifer mastitis, especially that caused by Staph. aureus.  
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